Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a brief blood thinner pause prevent bleeding without raising stroke risk?

NCT ID NCT05801068

Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This study looks at whether a predefined plan to pause and restart blood thinners (factor Xa inhibitors) around minor procedures—like dental work, cataract surgery, or routine endoscopy—can reduce bleeding in people with atrial fibrillation. It follows 2,500 adults who take rivaroxaban, apixaban, or edoxaban and are scheduled for a minor bleeding-risk procedure. The goal is to see if this approach lowers major bleeding within 30 days without increasing the chance of stroke or blood clots.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Factor Xa inhibitor (rivaroxaban, apixaban, or edoxaban) with a protocol for pausing and resuming around minor procedures
What this could lead to
If successful, this could provide a safer, standardized way to manage blood thinners around minor surgeries, reducing bleeding complications while protecting against strokes.
What could go wrong
This is an observational study, so it cannot prove cause and effect. Results may vary by patient and procedure, and there is always a risk of bleeding or clotting despite the protocol.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

2,500 people

The number who actually took part.

Started

Aug 2020

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged \>20 years * With rivaroxaban, apixaban, or edoxaban * History of non-valvular atrial fibrillation * Scheduled minor bleeding risk procedure(s) (dental procedure, cataract/glaucoma surgery, diagnostic GI endoscopy) Exclusion Criteria: * Pregnancy * With rivaroxaban or edoxaban at afternoon * Mental disorder * Contraindication to rivaroxaban, apixaban, edoxaban * Moderate or severe valvular heart disease, or with prosthetic heart valves * With antiplatelet drugs * History of systemic embolism or ischemic stroke within the last 12 months * scheduled therapeutic endoscopic procedure(s)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anticoagulant-induced bleeding are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anticoagulant-induced bleeding Atrial fibrillation

Contacts and locations

Locations

  • Seoul National university Hostpital

    Seoul, Jongno-gu, 03080, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.